Cover Image

Experience of organizing BCG therapy for localized bladder cancer in outpatient cancer care centers

Background. The clinical course of non-muscle-invasive bladder cancer is characterized by a tendency to develop local recurrences and the ability to tumor progression. The most effective method of preventing disease progression after transurethral resection of the bladder in patients of intermediate...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sergey A. Parts (Author), Yana V. Gridneva (Author), Maria I. Volkova (Author), Albert V. Oskarev (Author), Ogulshat R. Sinitsyna (Author), Evgeniya S. Kuzmina (Author), Vsevolod N. Galkin (Author), Saida M. Gadzhieva (Author)
Format:	Book
Published:	ZAO "Consilium Medicum", 2024-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Organizational models of cancer patient routing at the regional level
by: Sergey A. Parts, et al.
Published: (2023)

Efficacy of immunotherapy in small cell lung cancer: A retrospective stude
by: Marina A. Lyadova, et al.
Published: (2024)

Nano-BCG: A Promising Delivery System for Treatment of Human Bladder Cancer
by: Julieti Huch Buss, et al.
Published: (2018)

Dactilitis and oligoarthritis after BCG immunotherapy in a patient affected by bladder cancer
by: N. Elkhaldi, et al.
Published: (2011)

Macrophages directly kill bladder cancer cells through TNF signaling as an early response to BCG therapy
by: Mayra Fernanda Martínez-López, et al.
Published: (2024)

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients
by: Mark Kowalski, et al.
Published: (2010)

Novel therapies of treating non-muscle invasive bladder cancer when BCG therapy turns out to be insufficient
by: Magdalena Kołodziej, et al.
Published: (2024)

AIM2 inflammasome activation benefits the therapeutic effect of BCG in bladder carcinoma
by: Houhong Zhou, et al.
Published: (2022)

BCG downregulates PD1 and PD-L1 expression in bladder cancer cells co-cultivated with peripheral blood mononuclear cells
by: Katia R. M. Leite, et al.
Published: (2022)

Localized amyloidosis of the urinary bladder, clinically masquerading as bladder cancer
by: DeSouza Maria, et al.
Published: (2008)

Healthcare Resource Utilization and Cost Burden of BCG-Treated Non-Muscle Invasive Bladder Cancer Patients in Germany: A Retrospective Claims Analysis
by: Quignot N, et al.
Published: (2023)

Recent Advances in Drug Delivery Strategies for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Brief Review from 2018 to 2024
by: Feng Qu, et al.
Published: (2024)

Disseminated BCG sepsis following intravesical therapy for Bladder Carcinoma: A case report and review of literature
by: Oreoluwa Oladiran, et al.
Published: (2020)

Bladder Cancer Management of NMI and Muscle-Invasive Cancer
Published: (2017)

Local reactions after BCG vaccination in Japan
by: Kazushige Ikeda, et al.
Published: (2021)

Genomics of drug sensitivity in bladder cancer: an integrated resource for pharmacogenomic analysis in bladder cancer
by: Adnan Ahmad Ansari, et al.
Published: (2018)

Anlotinib Enhances the Therapeutic Effect of Bladder Cancer with GSDMB Expression: Analyzed from TCGA Bladder Cancer Database & Mouse Bladder Cancer Cell Line
by: Wang C, et al.
Published: (2023)

Results of the Monitoring for BCG Vaccination Complications
by: S.M. Liepshina, et al.
Published: (2015)

Future of TB Prevention: An Alternative To BCG
by: Sneka P, et al.
Published: (2022)

Bladder Cancer From Basic Science to Robotic Surgery
Published: (2012)

Vinflunine in the treatment of bladder cancer
by: Mark Bachner, et al.
Published: (2008)

Local Drug Delivery in Bladder Cancer: Advances of Nano/Micro/Macro-Scale Drug Delivery Systems
by: Irina V. Marchenko, et al.
Published: (2023)

Therapeutic Approach in Complications of BCG Vaccinations in Children
by: I.P. Zhurilo, et al.
Published: (2013)

BCG-osis after BCG vaccination in immunocompromised children: Case series and review
by: Soheila Shahmohammadi, et al.
Published: (2014)

BCG-osis after BCG vaccination in immunocompromised children: Case series and review
by: Soheila Shahmohammadi, et al.
Published: (2014)

Outcomes and Therapeutic Management of Bladder Cancer
Published: (2020)

Vulvar Metastasis from Bladder Cancer
by: Fouad Aoun, et al.
Published: (2015)

Opium and grade of urothelial bladder cancer
by: Shahryar Zeighami, et al.
Published: (2018)

Cancer-Associated Membrane Protein as Targeted Therapy for Bladder Cancer
by: Adlina Roslan, et al.
Published: (2022)

The Value of Extended Nursing Services on Patients with Bladder Cancer after Endoscopic Bladder Resection
by: Xueqin LI, et al.
Published: (2016)

Strategies to Get Drugs across Bladder Penetrating Barriers for Improving Bladder Cancer Therapy
by: Shupeng Wang, et al.
Published: (2021)

Nuclear Localization of COX-2 in relation to the Expression of Stemness Markers in Urinary Bladder Cancer
by: Raynoo Thanan, et al.
Published: (2012)

Modern Approach to Diagnosis and Treatment of Bladder Cancer
Published: (2021)

Knowledge-map analysis of bladder cancer immunotherapy
by: Zongwei Lv, et al.
Published: (2023)

Functional Nanomedicines for Targeted Therapy of Bladder Cancer
by: Chao Tang, et al.
Published: (2021)

Cost of illness of urothelial bladder cancer in Italy
by: Gerace C, et al.
Published: (2017)

Echographic and tomographic correspondence in the diagnosis of bladder cancer
by: Andrés Manuel Martín Rodríguez, et al.
Published: (2020)

Genetic susceptibility of bladder cancer in the Lebanese population
by: Hampig Raphael Kourie, et al.
Published: (2022)

Emerging molecular therapies in the treatment of bladder cancer
by: Scott D. Bell, et al.
Published: (2024)

Bladder Cancer - A Cinderella Cancer: Advances and Remaining Research Questions
Published: (2020)